What is the guideline‑directed medical therapy for heart failure with mid‑range ejection fraction (EF 41‑49%)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

GDMT for HFmrEF (EF 41-49%)

For patients with heart failure and mid-range ejection fraction (HFmrEF, EF 41-49%), initiate SGLT2 inhibitors (dapagliflozin 10 mg daily or empagliflozin 10-25 mg daily) as first-line therapy, followed by consideration of ARNI, MRA, and beta-blockers, though the evidence for these latter agents is weaker than in HFrEF. 1, 2

Current Guideline Framework

The 2025 Canadian guidelines have consolidated HFmrEF (EF 41-49%) and HFpEF into a unified category called "heart failure with nonreduced ejection fraction" (HFnrEF, LVEF >40%), recognizing that patients across this spectrum respond similarly to key pharmacotherapies 1. This represents an important paradigm shift from treating HFmrEF as a distinct entity.

Evidence-Based Treatment Hierarchy

Tier 1: SGLT2 Inhibitors (Strongest Evidence)

  • Dapagliflozin 10 mg daily or empagliflozin 10-25 mg daily 1
  • Class 2a recommendation in 2022 AHA/ACC/HFSA guidelines for HFmrEF 2
  • These agents reduce heart failure hospitalizations across the entire LVEF >40% spectrum
  • No titration required—start at target dose
  • Benefits extend beyond glycemic control to include preload/afterload reduction, improved myocardial efficiency through ketone metabolism, and natriuresis 1

Tier 2: Additional Therapies (Weaker Recommendations)

ARNI (Sacubitril-Valsartan):

  • Start 24/26 mg or 49/51 mg twice daily, target 97/103 mg twice daily 1
  • Class 2b recommendation for HFmrEF 2
  • Can be used as replacement for ACE-I/ARB 1

Mineralocorticoid Receptor Antagonists:

  • Spironolactone 12.5-25 mg daily (target 25-50 mg) or eplerenone 25 mg daily (target 50 mg) 1
  • Class 2b recommendation for HFmrEF 2
  • Monitor potassium and renal function closely—contraindicated if K+ ≥5.0 mEq/L or eGFR <30 mL/min/1.73m² 3

Beta-Blockers:

  • Class 2b recommendation for HFmrEF 2
  • Use evidence-based agents: bisoprolol, carvedilol, or metoprolol succinate
  • Retrospective data suggest dose-dependent mortality benefit in HFmrEF similar to HFrEF 4, 5

ARBs (if ARNI not used):

  • Candesartan 4-8 mg daily, target 32 mg daily 1
  • Class 2b recommendation 2

Tier 3: Emerging Therapies

GLP-1 Receptor Agonists (for select patients):

  • Semaglutide 0.25 mg weekly (target 2.4 mg weekly) or tirzepatide 2.5 mg weekly (target 15 mg weekly) 1
  • Consider particularly in patients with obesity and/or diabetes

Key Clinical Distinctions

HFmrEF more closely resembles HFrEF than HFpEF in terms of:

  • Higher prevalence of ischemic etiology 6, 7
  • Clinical characteristics and comorbidity profile 4
  • Response to neurohormonal blockade 4, 5, 8

However, the adjusted mortality risk is intermediate—lower than HFrEF but higher than HFpEF 4.

Critical Implementation Points

Initiation Strategy:

  • No specific sequence is mandated within treatment tiers 1
  • Individualize based on blood pressure, renal function, potassium, and comorbidities
  • SGLT2i should be prioritized given strongest evidence and Class 2a recommendation
  • Unlike HFrEF, there is no Class 1 recommendation for any single agent in HFmrEF

Dosing Philosophy:

  • Target doses from clinical trials are associated with better outcomes 4
  • Each mg equivalent of bisoprolol (HR 0.95) and ramipril (HR 0.95) shows incremental mortality reduction in HFmrEF 4
  • Uptitrate systematically rather than maintaining starting doses indefinitely

Monitoring for EF Changes:

  • LVEF frequently changes over time in HFmrEF 6
  • Patients transitioning from HFmrEF to HFrEF have worse prognosis 6
  • Those improving to HFpEF range should continue GDMT (concept of "HF with improved EF") 2
  • Repeat echocardiography at 3-6 months to reassess EF category

Common Pitfalls to Avoid

  1. Don't withhold therapy assuming HFmrEF is "mild"—these patients have significant morbidity and mortality risk
  2. Don't use non-evidence-based beta-blockers (e.g., atenolol, metoprolol tartrate)—only bisoprolol, carvedilol, and metoprolol succinate have mortality data
  3. Avoid triple neurohormonal blockade (ACE-I + ARB + MRA)—increases risk of hyperkalemia and renal dysfunction 9
  4. Don't use diltiazem or verapamil—they worsen HF outcomes 9
  5. Don't delay SGLT2i initiation—it can be started during or immediately after hospitalization with excellent safety profile 10

Practical Approach

Start with SGLT2i at target dose (no titration needed). Then add ARNI or ACE-I/ARB if blood pressure tolerates, followed by beta-blocker uptitration. Add MRA if patient remains symptomatic and renal function/potassium permit. Use diuretics as needed for congestion 1, 9.

The evidence base for HFmrEF is evolving but consistently shows benefit from therapies proven in HFrEF, particularly SGLT2i, supporting a proactive treatment approach rather than watchful waiting 4, 5, 6, 8.

References

4
Research

Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction.

Clinical research in cardiology : official journal of the German Cardiac Society, 2023

Related Questions

What are the treatment recommendations for patients with Cardiovascular (CV) disease and Heart Failure with mid-range ejection fraction (HFmrEF)?
What is the recommended initial guideline‑directed medical therapy for a patient with heart failure with reduced ejection fraction who has no diabetes mellitus and no hypertension?
What are the four evidence‑based pillars of disease‑modifying therapy for patients with heart‑failure with mildly reduced ejection fraction (EF 40‑49%)?
In patients with heart failure with reduced ejection fraction who are already on guideline‑directed therapy—including an ACE inhibitor or angiotensin receptor‑neprilysin inhibitor, an ARB, a sodium‑glucose co‑transporter‑2 inhibitor, a mineralocorticoid receptor antagonist, and a beta‑blocker—can digoxin be added to the beta‑blocker when they remain symptomatic or have recurrent heart‑failure admissions?
At what left‑ventricular ejection fraction should guideline‑directed heart‑failure therapy be initiated?
When is balloon dilation preferred over stent placement for biliary strictures?
How should I prescribe a low‑dose estradiol (7.5 µg per day) vaginal ring?
What are the recommended dosing and duration for Celestone (betamethasone) and cyclobenzaprine 10 mg in a patient with an acute low‑back strain?
How should I manage a patient with irritable bowel syndrome who has persistent abdominal spasms despite standard antispasmodic therapy?
What are the indications, dosing regimen, contraindications, and monitoring recommendations for teriparatide (recombinant parathyroid hormone) in adults with severe osteoporosis?
How should hypokalemia be managed in a 50‑year‑old woman with eGFR 69 mL/min/1.73 m² and serum potassium 3.1 mmol/L who is taking omeprazole (Prilosec), methotrexate, and meloxicam?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.